Serotonin News and Research

Latest Serotonin News and Research

New generation antidepressants may increase risk of adverse outcomes in elderly

Older people taking new generation antidepressants are at more risk of dying or suffering from a range of serious health conditions including stroke, falls, fractures and epilepsy, a study involving researchers at The University of Nottingham has found.

3 Aug 2011

CJ, RaQualia sign license agreement to develop and commercialize RQ-00000010 Partial Agonist

RaQualia Pharma Inc. today announced the signing of a license agreement with CJ CheilJedang Co. (CJ), granting CJ exclusive rights to develop, manufacture and commercialize RaQualia's 5-HT4 Partial Agonist in Korea, China, Taiwan, India and Southeast Asia.

30 Jul 2011

Patients who use anti-depressants more likely to suffer relapses

Patients who use anti-depressants are much more likely to suffer relapses of major depression than those who use no medication at all, concludes a McMaster researcher.

20 Jul 2011

Positive results from levomilnacipran Phase III study for major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Medicament today announced preliminary top-line results from a Phase III study of levomilnacipran for the treatment of adults with major depressive disorder (MDD).

18 Jul 2011

Viral toxin causes release of serotonin leading to vomiting

It is well known that viruses like rotavirus and norovirus are behind the majority of stomach infections. But it was unclear how vomiting developed, and the treatments available were oral fluid replacement and intravenous drips to prevent dehydration of the body.

18 Jul 2011

New antidepressant prescription linked to increased risk of falls in nursing home residents

Nursing home residents taking certain antidepressant medications are at an increased risk of falling in the days following the start of a new prescription or a dose increase of their current drug, according to a new study by the Institute for Aging Research of Hebrew SeniorLife, an affiliate of Harvard Medical School.

16 Jul 2011

Young investigators to receive Brain & Behavior Research Foundation awards

Brain & Behavior Research Foundation will honor five outstanding researchers at the Annual Klerman and Freedman Awards event in New York City.

15 Jul 2011

Neurochemical-producing probiotics can promote healthy gut and mind

Probiotics, often referred to as 'good bacteria', are known to promote a healthy gut, but can they promote a healthy mind? Exploring the new world of neurological probiotics, researchers in BioEssays present new ideas on how neurochemicals delivered directly to the gut, via probiotic intestinal microbiota, exert their beneficial effects in maintaining gastrointestinal health and even psychological well-being.

6 Jul 2011

Antidepressants during first trimester linked to increased risk of autism

Prenatal exposure to selective serotonin reuptake inhibitors, especially during the first trimester, is associated with a modest increase the risk of developing an autism spectrum disorder, according to a report published Online First in the Archives of General Psychiatry, one of the JAMA/Archives journals.

5 Jul 2011

Anti-depressants during early pregnancy linked to increased risk of autism

Exposure to selective serotonin reuptake inhibitors anti-depressants in early pregnancy may modestly increase risk of autism spectrum disorders, according to a Kaiser Permanente study published online in the current issue of Archives of General Psychiatry.

5 Jul 2011

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor, NBI-98854.

24 Jun 2011

Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

22 Jun 2011

Lorcaserin Phase 3 trial data on type 2 diabetes to be presented at ADA 2011

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that lorcaserin data from the Phase 3 BLOOM-DM trial will be presented in poster sessions at the American Diabetes Association's (ADA) 71st Scientific Sessions in San Diego, California.

21 Jun 2011

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

New findings from a multi-center, randomized, placebo-controlled clinical study of Deplin 15mg added to commonly prescribed antidepressants known as selective serotonin reuptake inhibitors showed that all patients who achieved remission at 30 days using Deplin 15mg adjuvant therapy, and who chose to enter a 12 month maintenance phase, maintained their remission after a year of treatment.

14 Jun 2011

Study finds notable prevalence of childhood abuse in migraine patients

A notable prevalence of childhood abuse - physical, sexual, verbal, or emotional - in migraine patients has been observed and documented over the last few years. In fact, it has emerged as a significant enough issue for the American Headache Society to devote an entire plenary session to it at its annual scientific conference in Washington this week.

2 Jun 2011